Carina Biotech files its first IND application for a CAR-T cell therapy targeting a solid cancer. The IND application is directed at a first-in-human Phase 1/2a clinical trial in advanced
Carina Biotech is pleased to announce that it has appointed Australian organisation Cell Therapies to undertake Good Manufacturing Processes (GMP) manufacture of its LGR5 CAR-T cells for a first-in-human clinical
Carina Biotech Symposium Program Wednesday, 18 May 2022 Hotel Grand Chancellor Adelaide + online Join from a PC, Mac, iOS or Android: https://unisa.zoom.us/j/86263467920?pwd=WXNCZCtTYkw4RTIyTUdNREpjbjlqZz09 Password: 720700 9:30 am – 10
PLEASE JOIN US on Wednesday, 18 May 2022 9:30 am – 5:00 pm for Carina Biotech's inaugural symposium Join us in Adelaide at the Hotel Grand Chancellor and virtually for Carina
Carina has had five abstracts accepted for poster presentations at the AACR Annual Meeting which will take place from April 8 to April 13. The poster presentations come after Carina’s
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a
"We can now conclude that CAR-T cells can actually cure patients" – Carl June, pioneering CAR-T scientist. Excerpts from the Endpoints article: "A decade after the first-ever patients were infused
In Forbes' 5 Biggest Biotech Trends for 2022, top of the list is personalised medicine – of which CAR-T therapy is an outstanding example of. CAR-T therapy harnesses the power
Carina Biotech has entered a license agreement with Bayerische Patentallianz (BayPAT) to the CXCR6-transduced CAR-T cell technology developed at the University Hospital of Ludwig-Maximillian University of Munich (LMU). The agreement
Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer in late
